CLIMB BIO, INC. Interest Receivable
CLIMB BIO, INC. (CLYM) had Interest Receivable of $1.37 million as of 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Balance Sheet › Assets
us-gaap:InterestReceivable · last filed 2025-05-14
- 2025-03-31: Interest Receivable $1.37M.
- 2024-12-31: Interest Receivable $1.12M.
- 2024-09-30: Interest Receivable $990.00K.
- 2023-12-31: Interest Receivable $440.00K.
| Period end | Interest Receivable |
|---|---|
| 2025-03-31 | $1.37M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $1.12M 10-Q · filed 2025-05-14 |
| 2024-09-30 | $990.00K 10-Q · filed 2024-11-12 |
| 2023-12-31 | $440.00K 10-K · filed 2025-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |